Geron Corp.
- GERN · Nasdaq
- Pharmaceutical Preparations
- Foster City, CA
- 258 employees
- CIK 0000886744
Updated from SEC filings through
Top things to know
Executives
-
Harout Semerjian President & CEO Form 4, November 16, 2026 - Timothy Williams EVP and Chief Legal Officer Form 4, April 14, 2026
- Ahmed ElNawawi Executive Vice President, Chief Commercial Officer 10-K, March 2, 2026
- John A. Scarlett, M.D. Former Chairman of the Board, President and Chief Executive Officer DEF 14A, April 7, 2026
-
Michelle J. Robertson Executive Vice President, Finance, Chief Financial Officer, Treasurer and Interim Secretary DEF 14A, April 7, 2026 - Andrew J. Grethlein, Ph.D. Former Executive Vice President, Chief Operating Officer DEF 14A, April 7, 2026
What leadership is saying
“Another quarter of strong RYTELO demand growth reinforces our confidence in the LR-MDS commercial opportunity and our ability to reach more second-line patients. Increased demand growth is being driven by the community practices which, in our view, indicates the potential for RYTELO to have a long growth runway in the U.S.”
Earnings press release (8-K Ex. 99.1), filed November 4, 2026
Geron Corp is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Foster City, CA. It trades as GERN on Nasdaq. Revenue was $237K in the fiscal year ending December 31, 2023, -60.2% from the year before. It reported about 258 employees. Harout Semerjian is President & CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | Not on file | Not on file | $237K 10-K, 2024-02-28 | $596K 10-K, 2024-02-28 | $1.4M 10-K, 2024-02-28 |
| Operating income | -$68.6M 10-K, 2026-03-02 | -$174M 10-K, 2026-03-02 | -$194M 10-K, 2026-03-02 | -$139M 10-K, 2025-02-27 | -$114M 10-K, 2024-02-28 |
| SG&A | $159M 10-K, 2026-03-02 | $146M 10-K, 2026-03-02 | $69.1M 10-K, 2026-03-02 | $43.6M 10-K, 2025-02-27 | $29.7M 10-K, 2024-02-28 |
| Net income | -$83.5M 10-K, 2026-03-02 | -$175M 10-K, 2026-03-02 | -$184M 10-K, 2026-03-02 | -$142M 10-K, 2025-02-27 | -$116M 10-K, 2024-02-28 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| | President & CEO | Form 4, November 16, 2026 |
| John A. Scarlett, M.D. | Named in proxy bio: Former Chairman of the Board, President and Chief Executive Officer | DEF 14A, April 7, 2026 |
| | Named in proxy bio: Executive Vice President, Finance, Chief Financial Officer, Treasurer and Interim Secretary | DEF 14A, April 7, 2026 |
| Timothy Williams | EVP and Chief Legal Officer | Form 4, April 14, 2026 |
| Andrew J. Grethlein, Ph.D. | Named in proxy bio: Former Executive Vice President, Chief Operating Officer | DEF 14A, April 7, 2026 |
| James Ziegler | Named in proxy bio: Former Executive Vice President, Chief Commercial Officer | DEF 14A, April 7, 2026 |
| Joseph Eid, M.D. | Named in proxy bio: Executive Vice President, Research & Development, Chief Medical Officer | DEF 14A, April 7, 2026 |
| Ahmed ElNawawi | Executive Vice President, Chief Commercial Officer | 10-K, March 2, 2026 |
| | Board member (per proxy) bio: director | DEF 14A, April 7, 2026 |
| Constantine Chinoporos | Board member (per proxy) bio: director | DEF 14A, April 7, 2026 |
| Elizabeth G. O'Farrell | Board member (per proxy) bio: director | DEF 14A, April 7, 2026 |
| John F. McDonald | Board member (per proxy) bio: director | DEF 14A, April 7, 2026 |
| Patricia S. Andrews | Board member (per proxy) bio: director | DEF 14A, April 7, 2026 |
| Robert J. Spiegel, M.D., FACP | Board member (per proxy) bio: director | DEF 14A, April 7, 2026 |
| Susan M. Molineaux, Ph.D. | Board member (per proxy) bio: director | DEF 14A, April 7, 2026 |
| V. Bryan Lawlis, Ph.D. | Board member (per proxy) bio: director | DEF 14A, April 7, 2026 |
What Geron Corp does
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO ® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California.
Press release "About" paragraph, 10-K for the year ending October 28, 2026
Shares and governance
| Shares outstanding | 644.2 million (as of October 30, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Public float | $861M (as of June 30, 2025) | 10-K, March 2, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 4, 2026 |
| Latest proxy statement | Meeting May 20, 2026 (filed April 7, 2026) | DEF 14A, April 7, 2026 |
| Auditor | Ernst & Young LLP (Iselin, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 16, 2026 | Timothy Williams EVP and Chief Legal Officer | Buy | 12,000 | $11K | Form 4, November 16, 2026 |
| November 13, 2026 | Harout Semerjian President & CEO | Buy | 53,500 | $51K | Form 4, November 16, 2026 |
| February 18, 2026 | Michelle Robertson EVP, CHIEF FINANCIAL OFFICER | Sale | 9,855 | $19K | Form 4, February 19, 2026 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-28
- Item 8.01 Other events
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-27
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-03-26
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-02-25
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-12
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-01-06
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2025-12-16
- Item 2.05 Costs associated with exit or disposal activities (restructuring)
- 8-K filed 2025-11-05
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Geron Corp
- What does Geron Corp do?
- In its own words, from Item 1 of its 10-K: "Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO ® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California."
- What is Geron Corp's revenue?
- $237K for the fiscal year ending December 31, 2023, from its 10-K filed February 28, 2024.
- Is Geron Corp profitable?
- Geron Corp reported net income of -$184M for the fiscal year ending December 31, 2023.
- How many employees does Geron Corp have?
- About 258 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Geron Corp?
- Harout Semerjian, President & CEO, as named in a 4 filed November 16, 2026.
- Where is Geron Corp headquartered?
- Foster City, CA.
- What is Geron Corp's stock ticker?
- GERN on Nasdaq.
- What industry is Geron Corp in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Geron Corp's website?
- geron.com.
- When does Geron Corp report earnings next?
- February 3, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is Geron Corp a public company?
- Yes. Geron Corp files with the SEC under CIK 0000886744 and trades as GERN.
- Who audits Geron Corp?
- Ernst & Young LLP, Iselin, New Jersey, as named in its latest annual report (10-K).
- How many shares of Geron Corp are outstanding?
- 644.2 million shares as of October 30, 2026, from its 10-Q filed November 4, 2026.
- What is Geron Corp's public float?
- $861M as of June 30, 2025, as reported on the cover of its 10-K filed March 2, 2026.
- How many business segments does Geron Corp report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 4, 2026.
- When is Geron Corp's annual shareholder meeting?
- May 20, 2026, per its proxy statement (DEF 14A) filed April 7, 2026.
- Have Geron Corp insiders traded stock recently?
- Since February 18, 2026, officers and directors reported 1 open-market sale worth about $19K and 2 purchases worth about $62K on Forms 4 and 5. The most recent: Timothy Williams (EVP and Chief Legal Officer) bought 12,000 shares on November 16, 2026.